30th Mar 2026 14:02
(Alliance News) - Abingdon Health PLC on Monday said it had won a series of contracts with a US-based customer to develop, scale up, and manufacture several lateral flow devices measuring multiple biomarkers.
The York, England-based life science firm providing rapid diagnostic tests said that the contracts have a total value of GBP4.8 million, and will be delivered in a period of about 27 months.
The contracts include full programme management, the management of regulatory processes, and analytical and clinical performance services.
Work on the new contracts will start immediately, and they will be executed via a series of work packages based on agreed milestones, with potential further scope beyond that period. There is also potential for the company to become the US customer's legal manufacturer.
Abingdon Health shares were up 5.9% to 7.68 pence each on Monday afternoon in London.
The work programmes will leverage Abingdon's existing capabilities in lateral flow tests development and manufacturing at its facilities in York, UK, and in Madison, Wisconsin. Regulatory services and performance evaluation services will be provided by services companies located at the company's facilities in Doncaster, UK.
Executive Chair Chris Hand said: "These contract wins reinforce our position as the 'go-to' experts for the provision of end-to-end lateral flow test development and programme management: in this case for complex multiplex quantitative test devices".
By Martin Miraglia, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Abingdon Healt.